Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lonza Inks Biotech Manufacturing Pacts
by Rick Mullin
November 2, 2009
| A version of this story appeared in
Volume 87, Issue 44
Swiss contract drugmaker Lonza will manufacture Alnara Pharmaceuticals’ lead product, liprotamase, at its site in Kourˇim, Czech Republic. The drug is a pancreatic-enzyme replacement therapy for patients with pancreatic insufficiency. Lonza also acquired a stake in Cilian, a German biotech company that uses the abilities of ciliates, eukaryotic single-cell organisms, to produce therapeutic proteins. The deal provides Lonza with access to technology and first right of refusal for commercial manufacturing of products.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X